[go: up one dir, main page]

ES2163020T3 - Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica. - Google Patents

Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.

Info

Publication number
ES2163020T3
ES2163020T3 ES96914826T ES96914826T ES2163020T3 ES 2163020 T3 ES2163020 T3 ES 2163020T3 ES 96914826 T ES96914826 T ES 96914826T ES 96914826 T ES96914826 T ES 96914826T ES 2163020 T3 ES2163020 T3 ES 2163020T3
Authority
ES
Spain
Prior art keywords
grf
analogs
body fat
growth hormone
chemical analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914826T
Other languages
English (en)
Inventor
Michel Ibea
Thierry Abribat
Paul Brazeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2163020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Application granted granted Critical
Publication of ES2163020T3 publication Critical patent/ES2163020T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANALOGOS DE CUERPO GRASO PRO COMO AGENTES ANABOLICOS Y EN EL DIAGNOSTICO Y TRATAMIENTO DE DEFICIENCIAS DE HORMONA DEL CRECIMIENTO. LOS ANALOGOS QUIMERICOS DE CUERPO GRASO OLA) Y PUEDEN SER PREPARADOS BIEN ANCLANDO UNA O VARIAS COLAS HIDROFOBAS AL GRF O BIEN SUSTITUYENDO UNO O VARIOS AMINOACIDOS CON UN RESIDUO PSEUDOMICELAR EN LA SINTESIS QUIMICA DE GRF. LOS ANALOGOS DE GRF DE LA PRESENTE INVENCION SON BIODEGRADABLES, NO INMUNOGENICOS Y MUESTRAN UNA POTENCIA ANABOLICA AUMENTADA CON UNA DOSIS REDUCIDA Y ACTIVIDAD PROLONGADA.
ES96914826T 1995-05-26 1996-05-22 Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica. Expired - Lifetime ES2163020T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22

Publications (1)

Publication Number Publication Date
ES2163020T3 true ES2163020T3 (es) 2002-01-16

Family

ID=27036979

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914826T Expired - Lifetime ES2163020T3 (es) 1995-05-26 1996-05-22 Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.

Country Status (13)

Country Link
US (2) US5939386A (es)
EP (1) EP0828758B1 (es)
JP (1) JP3576170B2 (es)
KR (1) KR100543190B1 (es)
AT (1) ATE204881T1 (es)
AU (1) AU697119B2 (es)
BR (2) BR9608799B1 (es)
CA (1) CA2222068C (es)
DE (1) DE69614849T2 (es)
DK (1) DK0828758T3 (es)
ES (1) ES2163020T3 (es)
PT (1) PT828758E (es)
WO (1) WO1996037514A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
BR0001606A (pt) * 1999-04-12 2001-04-24 Pfizer Prod Inc Composições de hormÈnio de crescimento e de hormÈnio de liberação de hormÈnio de crescimento
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
BR0113178A (pt) * 2000-08-02 2004-04-06 Theratechnologies Inc Peptìdeos biológicos modificados com potência aumentada
EP1205551A1 (en) * 2000-11-09 2002-05-15 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
CA2527039C (en) * 2003-05-29 2013-07-09 Theratechnologies Inc. Grf analog compositions and their use
CN1870893A (zh) 2003-09-12 2006-11-29 特西卡股份有限公司 胰岛素样生长因子－1(igf－1)缺陷的治疗方法
EP1675610A4 (en) * 2003-10-20 2010-04-28 Theratechnologies Inc USE OF GROWTH HORMONE RELEASE FACTOR ANALOGUE IN THE TREATMENT OF PATIENTS WITH EXCEPTION
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
US20130261058A1 (en) * 2010-09-16 2013-10-03 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
KR20140027284A (ko) 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US8871713B2 (en) 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
PL3445778T3 (pl) 2016-04-19 2021-02-22 Griffon Pharmaceuticals International Sa Pegylowane bioaktywne peptydy i ich zastosowania
CN120513087A (zh) * 2022-10-25 2025-08-19 星岩制药有限公司 用于肥胖症和其他疾病的组合疗法和轮换组合疗法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated growth hormone-releasing peptides and use thereof
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
DE69614849T2 (de) 2002-05-16
DE69614849D1 (de) 2001-10-04
JP3576170B2 (ja) 2004-10-13
US5939386A (en) 1999-08-17
KR19990021938A (ko) 1999-03-25
BR9608799B1 (pt) 2009-12-01
PT828758E (pt) 2002-02-28
WO1996037514A1 (en) 1996-11-28
AU697119B2 (en) 1998-09-24
EP0828758B1 (en) 2001-08-29
JPH11505807A (ja) 1999-05-25
EP0828758A1 (en) 1998-03-18
KR100543190B1 (ko) 2006-06-23
AU5683396A (en) 1996-12-11
US5861379A (en) 1999-01-19
BRPI9608799B8 (pt) 2019-11-05
DK0828758T3 (da) 2002-01-07
BR9608799A (pt) 1999-12-07
MX9709098A (es) 1998-06-30
CA2222068C (en) 2007-04-10
CA2222068A1 (en) 1996-11-28
ATE204881T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
ES2163020T3 (es) Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
AR023628A1 (es) Uso de un agente efectivo para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras para la preparacion de un medicamento utilpara estimular la hematopoyesis, util para incrementar el numero de celulas hematopoyeticas o celulas sanguineas maduras que acorta el tiempo en que
ES2187575T3 (es) Hexapeptidos ciclicos dotados de actividad antibiotica.
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
WO2000047236A8 (en) Matrices for drug delivery and methods for making and using the same
ES8701226A1 (es) Procedimiento de obtencion de una proteina de factor estimu-lante de colonias (csf) en primates
ES8103162A1 (es) Un procedimiento para la preparacion de interferon tipo ii.
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
ES2057537T3 (es) Sistema de dosificacion con emision continuada.
KR900701827A (ko) 치료용 펩타이드
RU2002135669A (ru) Олигопептиды
RU2000118976A (ru) Способ повышения продуктивности молодняка свиней
ATE61522T1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
DK1019037T3 (da) Lægemiddel indeholdende delta-aminolevulinsyre
ES2259377T3 (es) Preparado cosmetico con accion antiarrugas.
CN207520215U (zh) 生物电正牙牙套
ES2063950T3 (es) Una composicion terapeutica utilizada como solucion de irrigacion intraocular.
DE602004026840D1 (de) Physiologisch aktive peptide und medikamente, die diese enthalten
ES2213473B1 (es) Utilizacion de la melatonina para la regeneracion osea de uso humano yveterinario como producto activo.
RU2537026C2 (ru) Метод получения антиплацентарной крови, ее применение для профилактики и лечения послеродовых акушерско-гинекологических заболеваний у коров
LT5155B (lt) Naujas trijodotironino panaudojimas
薛绍白 et al. UPTAKE AND RETENTION OF HEMOTOPORPHYRIN DERIVATIVE (HPD) IN CONFLUENT AND UNCONFLUENT FORSKIN CELLS
HUT54388A (en) Process for producing new analogues of stimulator hormone for growth hormone secretion (grf)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 828758

Country of ref document: ES